Diligence memo · auto-generated · as of July 2, 2026
Vogenx, Inc.
Vogenx, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Vogenx, Inc. operates in Pharmaceuticals, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vogenx, Inc. has raised $750K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $750K on 2025-12-10.
Most recent recorded round closed around 2025-12-10.
Valuation (modeled)modeled
Provath models Vogenx, Inc. at approximately $1.5M (range $420K–$3.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 16% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Fedora Pharmaceuticals Inc., PRG FlowChem, Inc., Adora Animal Health Corp, ABLi Therapeutics, Inc., NextEvo, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.